HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

AIMS: Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events. METHODS AND RESULTS: Prior to randomization, 4...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Haynes, Richard, Jiang, Lixin, Hopewell, Jemma C, Li, Jing, Chen, Fang, Parish, Sarah, Landray, Martin J., Collins, Rory, Armitage, Jane, Collins, R., Armitage, J., Baigent, C., Chen, Z., Landray, M., Chen, Y., Jiang, L., Pedersen, T., Bowman, L., Chen, F., Hill, M., Haynes, R., Knott, C., Rahimi, K., Tobert, J., Sleight, P., Simpson, D., Parish, S., Baxter, A., Lay, M., Bray, C., Wincott, E., Leijenhorst, G., Skattebol, A., Moen, G., Mitchel, Y., Kuznetsova, O., MacMahon, S., Kjekshus, J., Hill, C., Lam, T.H., Sandercock, P., Peto, R., Hopewell, J.C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2013
Materias:
Fasttrack Clinical
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3640201/
https://ncbi.nlm.nih.gov/pubmed/23444397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/eht055
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares